Please note: This website includes an accessibility system. Press Control-F11 to adjust the website to people with visual disabilities who are using a screen reader; Press Control-F10 to open an accessibility menu.

A Holistic Approach to Diabetes Care: Reducing HbA1c and Weight with Emerging Pharmacotherapies

FACULTY

Silvio Inzucchi, MD
Professor of Medicine
Clinical Chief, Endocrinology
Medical Director, Yale Diabetes Center
Yale School of Medicine
Yale-New Haven Hospital
New Haven, CT

Anne L. Peters, MD
Professor of Clinical Medicine
USC Keck School of Medicine
Director, USC Clinical Diabetes Programs
Los Angeles, CA

PROGRAM OVERVIEW

This activity will explore strategies to improve glycemic and metabolic outcomes in patients with type 2 diabetes mellitus (T2DM). A review of clinical trial data will enable clinicians to personalize the selection of therapies for patients and examine the role of emerging dual GIP and GLP-1 receptor agonists in the management of type 2 diabetes and obesity.

TARGET AUDIENCE

This educational activity is intended for cardiologists, endocrinologists, primary care physicians, NPs, PAs, nurses, and other clinicians involved in the treatment of patients with T2DM.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be better able to:

  • Select therapies for the improvement of glycemic and extra-glycemic outcomes in patients with T2DM.
  • Determine the rationale for targeting GIP and GLP-1 receptors in the treatment of type2 diabetes and its metabolic comorbidities.
  • Identify patients in their own practice who may potentially benefit from treatments targeting GIP and GLP-1 receptors in the future based on knowledge of recent clinical data

PROVIDERS/GRANT SUPPORT

This activity is supported by a medical education grant from Lilly.

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 CreditsTM
Nurses — 1.0 Nursing Contact Hours

All other healthcare professionals completing this course will be issued a statement of participation

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the virtual live activity.

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

DISCLOSURE POLICY STATEMENT

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

DISCLOSURES OF CONFLICTS OF INTEREST

Faculty Member Disclosures
Silvio Inzucchi MD Consultant / Clinical Trial Committees: AstraZeneca, Boehringer-Ingelheim, Novo Nordisk, Merck/Pfizer, Lexicon, vTv Therapeutics, Abbott, Esperion
Lectures: AstraZeneca, Boehringer-Ingelheim
Anne Peters, MD Advisory Boards: Abbott, Astra-Zeneca, Lilly, NovoNordisk, Medscape, Zealand
Research: Abbott, Dexcom, Insulet
Stock Options: Teladoc, Omada Health

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.

INSTRUCTIONS FOR PARTICIPATION AND CREDIT

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.

Certificates will be emailed to the participant.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy-policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.